| Factor Information | |
|---|---|
| Data ID | 1344 |
| Factor | Morbidity |
| Description | Both univariate and multivariate analysis showed that HTK was associated with decreased early mortality (OR=0.151, P=0.035) and decreased morbidity (OR=0.167, P=0.000). Univariate and multivariate analysis showed that HTK is a statistically significant independent predictor of decreased early mortality and morbidity (P<0.05). |
| Biomarker | NA |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | treatment and risk assessment |
| Objective | The purpose of this study was to compare myocardial protection of HTK and St. Thomas’ crystalloid cardioplegic solution in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease. |
| p Value | <0.001 |
| OR | 0.167 |
| Conclusion | HTK solution seems to be an effective and safe alternative to St. Thomas’ solution for cardioplegic reperfusion in high-risk patients with complex congenital heart disease. |
| Risk Factor | protective factor |
| CHD Type | |
|---|---|
| ID | 521 |
| CHD Type | isolated CHD |
| CHD Subtype | D-TGA/VSD/CHD with PAH |
| Reference | |
|---|---|
| PMID | 27191607 |
| Year | 2016 |
| Title | Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution. |
| Sample | ||
|---|---|---|
| Population | Infants | |
| Source | Data | |
| Region | Beijing, China | |
| Method | Univariate and multivariate analysis | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | arterial switch operation | |
| Group | histidine-tryptophan-ketoglutarate (HTK) group(Treatment) | St group: control group, myocardial protection with conventional St. Thomas’ cold potassium crystalloid cardioplegic solution(Control) |
| Number | 18(total:75) | 17(total:26) |
| Age | 3.4±0.4 years | 1.9±0.4 years |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 18 (24%) | 17 (65.4%) |
